Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide

Arnt-Ole Tvenning,1,2 Christian Hedels,3 Jørgen Krohn,4,5 Dordi Austeng1,2 1Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, 7491 Trondheim, Norway; 2Department of Ophthalmology, St. Olavs Hos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tvenning AO, Hedels C, Krohn J, Austeng D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	drusenoid geographic atrophy anti-VEGF PDT Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/fe7e503b2040404ab28f5245773505a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe7e503b2040404ab28f5245773505a3
record_format	dspace
spelling	oai:doaj.org-article:fe7e503b2040404ab28f5245773505a32021-12-02T10:06:48ZTreatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide1177-5483https://doaj.org/article/fe7e503b2040404ab28f5245773505a32019-02-01T00:00:00Zhttps://www.dovepress.com/treatment-of-large-avascular-retinal-pigment-epithelium-detachments-in-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Arnt-Ole Tvenning,1,2 Christian Hedels,3 Jørgen Krohn,4,5 Dordi Austeng1,2 1Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, 7491 Trondheim, Norway; 2Department of Ophthalmology, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway; 3Hedels Eye Clinic, 6517 Kristiansund, Norway; 4Department of Clinical Medicine, Section of Ophthalmology, University of Bergen, 5021 Bergen, Norway; 5Department of Ophthalmology, Haukeland University Hospital, 5053 Bergen, Norway Purpose: To evaluate the use of aflibercept, triamcinolone acetonide, and photodynamic therapy (PDT) in the treatment of avascular pigment epithelium detachments (aPEDs). Patients and methods: Patients with treatment-naïve aPEDs ≥1,500 µm in diameter were randomized to treatment or observation. Treatment consisted of 6 monthly intravitreal injections of aflibercept. If the aPED persisted, the patients were treated with half-fluence PDT in combination with intravitreal triamcinolone acetonide and aflibercept. The primary outcome was change of best-corrected visual acuity (BCVA) after 24 months of follow-up. Secondary outcomes were changes in pigment epithelium volume, height and diameter, central retinal thickness, and number of patients developing choroidal neovascularization or geographic atrophy (GA). Results: Treatment and inclusion of patients were stopped after an interim analysis of 6-month data because 75% of the aPEDs were in different stages of GA. Nine patients with aPED were included in the study, of these one patient was excluded because of bilateral central serous chorioretinopathy. The remaining eight had drusenoid aPEDs. After 24 months of follow-up, estimated means of BCVA decreased by 4.2 and 20.8 letters in the treatment and observation group, respectively. This decrease over time was not significantly different between groups (P=0.140, 95% CI -5.3, 38.6). Estimated means of PED volume, height, diameter, and central retinal thickness were not significantly different between groups. Choroidal neovascularization and retinal pigment epithelium tear developed in one patient in the treatment group. One patient in the treatment group and two patients in the observation group progressed to complete retinal pigment epithelium and outer retinal atrophy. A decrease in PED volume was associated with the development of complete retinal pigment epithelium and outer retinal atrophy (P=0.029). Conclusion: This small trial indicates that multitargeted, primarily antiangiogenic therapy does not favorably alter the natural course of drusenoid aPEDs. Keywords: drusenoid, geographic atrophy, anti-VEGF, PDTTvenning AOHedels CKrohn JAusteng DDove Medical Pressarticledrusenoidgeographic atrophyanti-VEGFPDTOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 233-241 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	drusenoid geographic atrophy anti-VEGF PDT Ophthalmology RE1-994
spellingShingle	drusenoid geographic atrophy anti-VEGF PDT Ophthalmology RE1-994 Tvenning AO Hedels C Krohn J Austeng D Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide
description	Arnt-Ole Tvenning,1,2 Christian Hedels,3 Jørgen Krohn,4,5 Dordi Austeng1,2 1Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, 7491 Trondheim, Norway; 2Department of Ophthalmology, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway; 3Hedels Eye Clinic, 6517 Kristiansund, Norway; 4Department of Clinical Medicine, Section of Ophthalmology, University of Bergen, 5021 Bergen, Norway; 5Department of Ophthalmology, Haukeland University Hospital, 5053 Bergen, Norway Purpose: To evaluate the use of aflibercept, triamcinolone acetonide, and photodynamic therapy (PDT) in the treatment of avascular pigment epithelium detachments (aPEDs). Patients and methods: Patients with treatment-naïve aPEDs ≥1,500 µm in diameter were randomized to treatment or observation. Treatment consisted of 6 monthly intravitreal injections of aflibercept. If the aPED persisted, the patients were treated with half-fluence PDT in combination with intravitreal triamcinolone acetonide and aflibercept. The primary outcome was change of best-corrected visual acuity (BCVA) after 24 months of follow-up. Secondary outcomes were changes in pigment epithelium volume, height and diameter, central retinal thickness, and number of patients developing choroidal neovascularization or geographic atrophy (GA). Results: Treatment and inclusion of patients were stopped after an interim analysis of 6-month data because 75% of the aPEDs were in different stages of GA. Nine patients with aPED were included in the study, of these one patient was excluded because of bilateral central serous chorioretinopathy. The remaining eight had drusenoid aPEDs. After 24 months of follow-up, estimated means of BCVA decreased by 4.2 and 20.8 letters in the treatment and observation group, respectively. This decrease over time was not significantly different between groups (P=0.140, 95% CI -5.3, 38.6). Estimated means of PED volume, height, diameter, and central retinal thickness were not significantly different between groups. Choroidal neovascularization and retinal pigment epithelium tear developed in one patient in the treatment group. One patient in the treatment group and two patients in the observation group progressed to complete retinal pigment epithelium and outer retinal atrophy. A decrease in PED volume was associated with the development of complete retinal pigment epithelium and outer retinal atrophy (P=0.029). Conclusion: This small trial indicates that multitargeted, primarily antiangiogenic therapy does not favorably alter the natural course of drusenoid aPEDs. Keywords: drusenoid, geographic atrophy, anti-VEGF, PDT
format	article
author	Tvenning AO Hedels C Krohn J Austeng D
author_facet	Tvenning AO Hedels C Krohn J Austeng D
author_sort	Tvenning AO
title	Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide
title_short	Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide
title_full	Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide
title_fullStr	Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide
title_full_unstemmed	Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide
title_sort	treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/fe7e503b2040404ab28f5245773505a3
work_keys_str_mv	AT tvenningao treatmentoflargeavascularretinalpigmentepitheliumdetachmentsinagerelatedmaculardegenerationwithafliberceptphotodynamictherapyandtriamcinoloneacetonide AT hedelsc treatmentoflargeavascularretinalpigmentepitheliumdetachmentsinagerelatedmaculardegenerationwithafliberceptphotodynamictherapyandtriamcinoloneacetonide AT krohnj treatmentoflargeavascularretinalpigmentepitheliumdetachmentsinagerelatedmaculardegenerationwithafliberceptphotodynamictherapyandtriamcinoloneacetonide AT austengd treatmentoflargeavascularretinalpigmentepitheliumdetachmentsinagerelatedmaculardegenerationwithafliberceptphotodynamictherapyandtriamcinoloneacetonide
_version_	1718397687358816256

Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide

Ejemplares similares